Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Dashboard
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
Membership Levels
By The Numbers
Press Releases
1493 Articles Available
1
63
Can't find what you're looking for? Try our
advanced search
.
Response
Allergan Responds to Public Shareholder Letter
PR-M02-19-NI-047
Agreement
Eisai and Empatica Enter an Agreement to Co-Promote the Embrace2 Device for People Living With Epilepsy in the U.S.
PR-M02-19-NI-048
Generics
Sandoz Inc. Launches Authorized Generic Version of Buprenorphine and Naloxone Sublingual Film
PR-M02-19-NI-045
Research
Diabetes Research Institute Scientists Engineer 'Suicide Genes' to Safely Grow Insulin-Producing Beta Cells from Stem Cells
PR-M02-19-NI-046
Diabetes
FDA Authorizes First Interoperable Insulin Pump Intended to Allow Patients to Customize Treatment Through Their Individual Diabetes Management Devices
PR-M02-19-NI-044
Blood Plasma
The Global Cold Plasma Market Size is Expected to Reach USD 198.50 Million by 2026 at a Strong CAGR of 15.2%
PR-M02-19-NI-043
M&A
Lilly Completes Acquisition of Loxo Oncology
PR-M02-19-NI-041
IPO
Stealth BioTherapeutics Announces Pricing of Initial Public Offering
PR-M02-19-NI-042
FDA Statement
Statement from FDA Commissioner Scott Gottlieb, M.D., On New Policy to Improve Access for Drugs that Face Inadequate Generic Competition
PR-M02-19-NI-039
FDA
FDA Advances New Efforts to Promote Development of Safe and Effective Regenerative Medicine Products
PR-M02-19-NI-037
Oncology
Bayer to Obtain Full Rights to Global Development and Commercialization of Oncology Compounds Vitrakvi® (larotrectinib) and BAY 2731954 (LOXO-195)
PR-M02-19-NI-040
Clinical Trials
Avapritinib Receives Phase III Clinical Trial Approval for GIST in China
PR-M02-19-NI-038
Acquisition
Johnson & Johnson Announces Agreement to Acquire Auris Health, Inc.
PR-M02-19-NI-036
FDA Statement
Statement from FDA Commissioner Scott Gottlieb, M.D. on New Programs to Promote the Adoption of Innovations in Drug Manufacturing
PR-M02-19-NI-034
Collaboration
Abilita Bio and Amgen Enter Into a Multi-Target Collaboration
PR-M02-19-NI-035
Expansion
Discovery Life Sciences Launches Major European Expansion
PR-M02-19-NI-033
FDA Statement
Statement from FDA Commissioner Scott Gottlieb, M.D., on Ongoing Efforts to Secure the U.S. Supply Chain and Confront the Opioid Epidemic
PR-M02-19-NI-032
Immunotherapy
AIVITA Identifies Mechanism to Enhance Patient Response Rate to Next Generation Cancer Stem Cell Immunotherapy
PR-M02-19-NI-031
FDA
FDA Advisory Committee Recommends Approval of SPRAVATO™ (esketamine) Nasal Spray CIII for Adults with Treatment-Resistant Depression
PR-M02-19-NI-030
Oncology
Cure Rate Exceeds 97 Percent in Retrospective Study of Sensus Healthcare's SRT-100™ for Treating Basal and Squamous Cell Carcinomas of the Lower Extremities
PR-M02-19-NI-029
Genetic Testing
Invitae Launches Non-Invasive Prenatal Screening (NIPS), Offering In-Depth Genetic Information in Early Pregnancy
PR-M02-19-NI-031
License Agreement
Applied Biology to Enter into a License Agreement with Hairmore for its Novel Treatment for Traction Alopecia
PR-M02-19-NI-030
Funding
Culture Biosciences Secures $5.5M to Pioneer Biomanufacturing-as-a-Service
PR-M02-19-NI-029
FDA Approval
U.S. FDA Approves DARZALEX® (daratumumab) Split-Dosing Regimen
PR-M02-19-NI-028
1
63
»
